Prostate cancer trials in Australia

In Australia 82 Also abroad 1481

82 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Adelaide, Darlinghurst, Herston, Malvern
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 3Taking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
Brisbane, Clayton, Macquarie University, Melbourne, Westmead
Age
18 years and over
People
1,314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
Phase 3Taking people
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Auchenflower, Clayton, East Melbourne, Southport, Waratah, Woolloongabba
Age
18 years and over
People
750 worldwide
Run by
Amgen
See details and how to joinNCT07213674
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Darlinghurst, Kurralta Park, Melbourne, Murdoch
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 1Taking people
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Where
East Melbourne
Age
18 years and over
People
136 worldwide
Run by
AstraZeneca
See details and how to joinNCT06879041
Phase 3Taking people
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Where
Southport
Age
18 years and over
People
736 worldwide
Run by
BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00
Phase 3Taking people
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Where
Adelaide, Darlinghurst, Malvern, Murdoch
Age
18 years to 100 years
People
940 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06855277
Phase 1/2Taking people
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Where
Malvern, Melbourne, Murdoch
Age
18 years and over
People
123 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07226986 · EU 2025-521859-23-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Kingswood, Murdoch, Orange, South Brisbane, St Leonards, Waratah, Woolloongabba
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Kurralta Park, Nedlands, Orange, South Brisbane, Wahroonga
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Where
North Adelaide
Age
18 years to 99 years
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT07590934
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Macquarie University
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 1/2Taking people
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Where
Liverpool, Melbourne, St Leonards
Age
18 years and over
People
188 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00
Phase 1/2Taking people
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Where
Darlinghurst, Melbourne
Age
18 years to 100 years
People
42 worldwide
Run by
AstraZeneca
See details and how to joinNCT07529717
Phase 1Not yet taking people in Australia
A Study of KMV002 in Patients With mAPMR Prostate Cancer
Where
East Melbourne, North Ryde
Age
18 years to 80 years
People
24
Run by
Chimivac INC
See details and how to joinNCT07866300
Phase 1/2Taking people
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Where
Melbourne, South Brisbane
Age
18 years and over
People
619 worldwide
Run by
Parabilis Medicines, Inc.
See details and how to joinNCT05919264
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Darlinghurst, Melbourne, Randwick
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1Taking people
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Where
Adelaide, Darlinghurst, Liverpool, Macquarie
Age
18 years and over
People
180 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Bedford Park, Camperdown, Clayton, Nedlands, South Brisbane
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Where
Auchenflower
Age
18 years and over
People
684 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07802704 · EU 2026-525558-13-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Albury, Birtinya, Brisbane, Saint Leonards, Sydney
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 1/2Taking people
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Where
Camperdown, Wollongong
Age
18 years and over
People
181 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00
No phaseTaking people
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Where
Fitzroy, Melbourne
Age
18 years and over
People
84 worldwide
Run by
Palette Life Sciences, Inc.
See details and how to joinNCT06496256
Phase 1Taking people
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Where
Bendigo, Douglas, Geelong, Tugun
Age
18 years and over
People
83 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07277270 · EU 2025-522274-37-00
Phase 1Taking people
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
Where
Adelaide, Brisbane, Gold Coast, Melbourne, Sydney
Age
18 years to 80 years
People
320 worldwide
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07711184